Following its recent acquisition by St James MGP Limited, ReNeuron Holdings PLC has now completed its re-registration as a private company under its new name, ReNeuron (UK) Limited. Effective 1 October, Dr Martin Edwards has resigned as Chief Executive Officer and will leave the ReNeuron Board to take up a position at Novo A/S. Also effective from this date, Michael Hunt, currently Chief Financial Officer, is appointed Chief Operating Officer.
Mark Clement, Chief Executive Officer of Merlin Biosciences, and Mark Docherty, Investment Director at Merlin Biosciences, have joined the ReNeuron Board as non-executive Directors. Professor Trevor Jones will continue as non-executive Chairman, his fellow directors now being Mark Clement and Mark Docherty (representing both Merlin and St James’s MGP Limited), together with Michael Hunt and Dr John Sinden (Chief Scientific Officer).
Professor Jones said:
On behalf of the Board, I should like to offer my sincerest thanks to Martin Edwards for his significant contribution to ReNeuron’s success to date, and to wish him well in his next endeavour. I should also like to congratulate Michael Hunt on his appointment as Chief Operating Officer and to welcome Mark Clement and Mark Docherty to the Board.
ReNeuron’s core stem cell technology continues to carry great promise, and I am pleased and excited to remain involved with the Company as it enters its next phase of development.’
Notes to editors
ReNeuron is a UK bio-pharmaceutical company developing proprietary treatments for neurological disorders. Its focus is the development of innovative neural stem cell transplantation technology for the treatment of brain diseases such as Parkinson’s disease, Huntington’s disease and stroke. The Company is also exploiting the use of its stem cell lines as a drug discovery platform through its ReNcell product, which is marketed to pharmaceutical companies and academia for use as a drug discovery tool and for general research. ReNeuron’s stem cells also have the capability to form neural networks suitable for use in biosensors, currently being developed as a potential detection tool to combat bio-terrorism or as a drug-screening tool in the pharmaceutical industry.
Professor Trevor Jones
+ 44 (0)207 930 3477
Michael Hunt ReNeuron (UK) Limited
+44 (0)1483 302560